Following a full submission.
Valsartan (Diovan) is accepted for restricted use within NHS Scotland to improve survival following myocardial infarction (MI) in clinically stable patients with signs, symptoms or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.
Valsartan has been shown to be as effective as the ACE inhibitor, captopril, in this patient population and should be considered a second-line alternative in patients who cannot tolerate an ACE inhibitor. The economic evaluation demonstrates that valsartan is only cost-effective in the patient population that is intolerant of ACE inhibitors.
Download detailed advice44KB (PDF)
- Medicine name:
- Valsartan 40mg, 80mg and 160mg capsules and tablets (Diovan®)
- SMC ID:
- Left ventricular failure and/or left ventricular systolic dysfunction
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Date advice published
- 09 May 2005